EUROAPI announced the completion of the acquisition of BianoGMP, strengthening its CDMO expertise in the high-growth oligonucleotide market.
This acquisition further differentiates EUROAPI’s value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization.
As planned, Biano will retain its corporate brand and become a EUROAPI company.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!